Federal Register
Notice: FDA is seeking comments on the information collection contained in the guidance for industry on Continuous Marketing Applications: Pilot 2 —Scientific Feedback and Interactions During Development of Fast Track Products Under the Prescription Drug User Fee Act. To view this notice, click here.